Table 1.
Characters of included 32 papers about the prognostic value of miR-221 in human carcinomas
| Study | Nation | Patients | cancer | Survival | HR(95% CI) | P value | Origins | Measure | Cutoff | Analysis |
|---|---|---|---|---|---|---|---|---|---|---|
| Wu Q (2017) | China | 74 | Ovarian cancer | OS | 0.395 (0.196–0.796) | 0.009 | Tumor | qRT-PCR | Median | Univariate |
| Tsikrika (2017) | Greece | 159 | Bladder cancer |
DFS PFS |
0.712(0.380–1.335) 1.396(0.539–3.620) |
0.290 0.492 |
Tumor | qRT-PCR | ROC | Univariate |
| Deng (2017) | China | 125 | Breast cancer | DFS | 0.480 (0.263–0.879) | 0.017 | Tumor | qRT-PCR | Median | Multivariate |
| Nakka (2017) | USA | 32 | Osteosarcoma | OS | 0.733(0.486–1.1055) | 0.139 | Tumor | qRT-PCR/ISH | Quartation | Multivariate |
| Xie D (2017) | China | 70 | Live cancer | OS | 1.743 (1.004–3.772) | 0.012 | Tumor | qRT-PCR | Median | Multivariate |
| Hussein (2017) | Egypt | 50 | Laryngeal cancer | OS | 6.5 (1.8–22.5) | 0.003 | Tumor | qRT-PCR | ROC | Univariate |
| Dai L (2017) | China | 78 | Thyroid cancer | RFS | 1.41(1.14–1.95) | 0.007 | Tumor | qRT-PCR | Median | Multivariate |
| Chen F (2017) | China | 135 | HCC |
DFS OS |
2.846 (1.564–5.181) 2.969 (1.629–5.408) |
0.001 < 0.001 |
Tumor | qRT-PCR | Median | Multivariate |
| Zhang Y (2016) | China | 104 | Lung cancer | OS | 1.873(1.267–2.768) | 0.002 | Tumor | qRT-PCR | Median | Multivariate |
| Yang Z (2015) | China | 108 | Osteosarcoma |
OS RFS |
7.66(1.83–15.92) 6.82(1.33–13.69) |
0.01 0.01 |
Serum | qRT-PCR | Median | Multivariate |
| Cai K (2015) | China | 182 | Colon cancer | OS | 2.394 (1.210–4.910) | 0.006 | Tumor | qRT-PCR | Median | Multivariate |
| Tao K (2014) | China | 90 | Colon cancer | OS | 2.043 (1.095–3.812) | 0.025 | Tumor | qRT-PCR | Median | Multivariate |
| Vergho (2014) | Germany | 74 | Renal cancer | CSS | 0.47 (0.22–1.00) | 0.0527 | Tumor | qRT-PCR | ROC | Multivariate |
| Lv J (2014) | China | 117 | Lung cancer | OS | 2.425 (1.314–4.475) | 0.005 | Tumor | qRT-PCR | Median | Multivariate |
| Li P (2014) | China | 72 | CMM |
OS DFS |
3.189(1.782–6.777) 2.119(1.962–8.552) |
0.007 0.01 |
Serum | qRT-PCR | Median | Multivariate |
| Gyongyosi B (2014) | Italy | 20 | HCC |
OS PFS |
1.92(0.61–6.10) 1.32(0.47–3.66) |
0.29 0.58 |
Tumor | qRT-PCR | Median | Univariate |
| Falkenberg (2013) | Germany | 86 | Breast cancer | MFS | 2.57(1.1073–5.9647) | 0.028 | Tumor | qRT-PCR | ROC | Multivariate |
| Hong (2013) | China | 96 | Ovarian cancer | OS | 2.243(1.1357–4.4300) | 0.020 | Serum | qRT-PCR | Mean | Multivariate |
| Gimenes (2013) | Brazil | 48 | ALL |
OS DFS |
2.31(0.92–5.81) 1.54 (0.57–4.17) |
0.074 0.391 |
Marrow | qRT-PCR | Median | Multivariate |
| Karakatsanis (2013) | Greece | 60 | HCC | OS | 1.72 (1.32–2.50) | 0.002 | Tumor | qRT-PCR | Mean | Multivariate |
| Amankwah (2013) | USA | 65 | Prostate cancer | RFS | 1.79 (0.67–4.76) | 0.25 | Tumor | qRT-PCR | Median | Multivariate |
| Liu K (2012) | China | 92 | Gastric cancer | OS | 2.322 (1.1116–4.8505) | 0.025 | Tumor | qRT-PCR | Mean | Multivariate |
| Hanna (2012) | USA | 377 | Breast cancer | OS | 0.70 (0.51–0.97) | 0.0312 | Tumor | ISH | Quartation | Multivariate |
| Kang (2012) | Korea | 92 | Prostate cancer | RFS | 0.360 (0.171–1.896) | 0.570 | Tumor | qRT-PCR | Median | Univariate |
| Li J (2011) | China | 46 | HCC | OS | 1.903(1.235–2.981) | 0.018 | Serum | qRT-PCR | Mean | Multivariate |
| Yoon (2011) | Korea | 115 | HCC | RFS | 3.07 (1.56–6.07) | 0.001 | Tumor | qRT-PCR | Mean | Multivariate |
| Zhao R (2011) | China | 93 | Breast cancer | OS | 6.871 (1.967–23.997) | 0.003 | plasma | qRT-PCR | Median | Multivariate |
| Schaefer (2010) | Germany | 75 | Prostate cancer | RFS | 0.93 (0.3–2.89) | 0.902 | Tumor | qRT-PCR | Median | Univariate |
| Wang (2010) | China | 32 | ALL | OS | 0.538(0.30–0.9648) | 0.038 | Marrow | qRT-PCR | Median | Multivariate |
| Spahn (2010) | Germany | 92 | Prostate cancer | RFS | 0.525(0.29–0.95) | 0.032 | Tumor | qRT-PCR | ROC | Multivariate |
| Pu (2010) | China | 103 | Colon cancer | OS | 3.478(1.038–11.654) | 0.043 | Plasma | qRT-PCR | Youden | Multivariate |
| Guo (2010) | China | 79 | Lymphoma | OS | 5.714(1.782–18.18) | 0.003 | Plasma | qRT-PCR | Youden | Multivariate |
Note: HCC Hepatocellular carcinoma; ALL Acute lymphoid leukemia; CMM Cutaneous malignant melanoma; ROC Receiver operating characteristic curve; Youden, Youden index; OS Overall survival; RFS Relapse-free survival; DFS Disease-free survival; PFS Progression-free survival; CSS Cancer-special survival; MFS Metastasis-free survival; qRT-PCR Quantitative Real Time PCR; ISH In-situ hybridization